Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/178677
Title: | How to use the harmonising outcome measures for eczema core outcome set for atopic dermatitis trials: a users' guide | Authors: | Thomas, Kim S. Howells, Laura Leshem, Yael A. Simpson, Eric L. Apfelbacher, Christian Spuls, Phyllis I. Gerbens, Louise A. A. Jacobson, Michael E. Katoh, Norito Williams, Hywel C. Stuart, Beth L. |
Keywords: | Medicine, Health and Life Sciences | Issue Date: | 2024 | Source: | Thomas, K. S., Howells, L., Leshem, Y. A., Simpson, E. L., Apfelbacher, C., Spuls, P. I., Gerbens, L. A. A., Jacobson, M. E., Katoh, N., Williams, H. C. & Stuart, B. L. (2024). How to use the harmonising outcome measures for eczema core outcome set for atopic dermatitis trials: a users' guide. British Journal of Dermatology, 190(4), 527-535. https://dx.doi.org/10.1093/bjd/ljad497 | Journal: | British Journal of Dermatology | Abstract: | Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed to maximize its uptake. Objectives: To provide answers to some of the commonly asked questions about using the HOME COS; to provide data to help with the interpretation of trial results; and to support sample size calculations for future trials. Methods and results: We provide practical guidance on the use of the HOME COS for investigators planning clinical trials in patients with AD. It answers some of the common questions about using the HOME COS, how to access the outcome measurement instruments, what training/resources are needed to use them appropriately and clarifies when the COS is applicable. We also provide exemplar data to inform sample size calculations for eczema trials and encourage standardized data collection and reporting of the COS. Conclusions: By encouraging adoption of the COS and facilitating consistent reporting of outcome data, it is hoped that the results of eczema trials will be more comprehensive and readily combined in meta-analyses and that patient care will subsequently be improved. | URI: | https://hdl.handle.net/10356/178677 | ISSN: | 0007-0963 | DOI: | 10.1093/bjd/ljad497 | Schools: | Lee Kong Chian School of Medicine (LKCMedicine) | Rights: | © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | LKCMedicine Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ljad497.pdf | 1.07 MB | Adobe PDF | ![]() View/Open |
SCOPUSTM
Citations
50
3
Updated on Mar 16, 2025
Page view(s)
98
Updated on Mar 18, 2025
Download(s) 50
21
Updated on Mar 18, 2025
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.